APGE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Apogee Therapeutics (APGE) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock has strong hedge fund interest, positive analyst sentiment with high price targets, and potential long-term growth catalysts in its pipeline. Despite recent price pullbacks, these are seen as buying opportunities by analysts. The technical indicators and options data also suggest a neutral to slightly bullish sentiment, making this a favorable entry point.
The technical indicators show a mixed but slightly bullish trend. The MACD is positive at 0.68, indicating bullish momentum, while the RSI is neutral at 49.004. The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its pivot level of 69.723, with support at 66.743 and resistance at 72.702. These suggest the stock is in a consolidation phase with potential for upward movement.
Hedge funds are heavily buying the stock, with a 2216.65% increase in buying activity last quarter.
Analysts view the recent selloff as an overreaction and maintain high price targets ranging from $83 to $
Positive Phase 1b data for zumilokibart in asthma and its potential as a dual-label drug for asthma and atopic dermatitis provide strong long-term growth prospects.
Great Point Partners and Perceptive Advisors have significantly increased their stakes in the company.
The stock has recently experienced a 12% selloff due to concerns over competitor data and potential risks in the OX40 class.
RBC downgraded the stock to Sector Perform, citing valuation concerns and a crowded market.
Wolfe Research highlighted potential negative catalysts in the first half of the year.
In Q3 2025, the company reported a net income loss of $65.02M, which improved by 32.65% YoY. EPS also improved to -1.11, up 29.07% YoY. While the company is not yet profitable, its financials show improving trends, and it has guided a cash runway into the second half of 2028.
Analysts are generally bullish on the stock, with multiple Buy ratings and price targets as high as $137. Citi and UBS view the recent selloff as a buying opportunity, while RBC downgraded the stock due to valuation concerns. Overall, the consensus is positive, with strong confidence in the company's pipeline and long-term potential.
